RT Journal文章SR电子T1 Mepolizumab效果和鉴定严重哮喘JF欧洲呼吸期刊Jo Eur Respir J FD欧洲呼吸学会SP 1902420 Do 10.1183 / 13993003.02420-2019 VO 55是5 A1 Harvey，Erin S. A1 Langton，188bet官网地址David A1 Katelaris，Contance A1 Stevens，Sean A1 Filhman，Andrew A1 Harrington，John A1 Harington，Mark A1 Kritikos，Vicky A1 Radhakrishna，Naghmeh A1 Bardin，Philip A1 Peters，Matthew A1 Reynolds，Paul N. A1upham，John W. A1 Baraket，Melissa A1 Bowler，Simon A1 Bowden，Jeffrey A1 Chien，Jimmy A1 Chung，Li Ping A1 Graing，Christopher A1 Jenkins，Christine A1 Katsourotos，Gregory P.A1 Lee，Joy A1 McDonald，Vanessa M.A1 Reddel, Helen K. A1 Rimmer, Janet A1 Wark, Peter A.B. A1 Gibson, Peter G. YR 2020 UL //www.qdcxjkg.com/content/55/5/1902420.abstract AB Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population.The Australian Mepolizumab Registry (AMR) was established with an aim to assess the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia.Patients (n=309) with severe eosinophilic asthma (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control (median Asthma Control Questionnaire (ACQ)-5 score of 3.4), frequent exacerbations (median three courses of oral corticosteroids (OCS) in the previous 12 months), and 47% required daily OCS. Median baseline peripheral blood eosinophil level was 590 cells·µL−1. Comorbidities were common: allergic rhinitis 63%, gastro-oesophageal reflux disease 52%, obesity 46%, nasal polyps 34%.Mepolizumab treatment reduced exacerbations requiring OCS compared with the previous year (annualised rate ratio 0.34 (95% CI 0.29–0.41); p<0.001) and hospitalisations (rate ratio 0.46 (95% CI 0.33–0.63); p<0.001). Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline.Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.In clinical practice, mepolizumab reduces the burden of severe eosinophilic asthma by reducing severe exacerbations and improving asthma control, quality of life and lung function. Super-responders have a T2 phenotype and few comorbidities. http://bit.ly/2UIio4x